Recombinant Mouse VSIG4 His-tag Protein, CF

Catalog #: 9747-VS Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
9747-VS-050

Recombinant Mouse VSIG4 His-tag Protein Bioactivity

1 Image

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Mouse VSIG4 His-tag Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC). The ED₅₀ for this effect is 0.5-2.5 μg/mL.

Source

Mouse myeloma cell line, NS0-derived mouse VSIG4 protein
His20-Pro187, with a C-terminal 6-His tag

Accession #

NP_808457

N-terminal Sequence
Analysis

His20

Predicted Molecular Mass

20 kDa

SDS-PAGE

29-38 kDa, reducing conditions

Product Datasheets

9747-VS

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

9747-VS

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 200 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Mouse VSIG4 (Catalog # 9747-VS) inhibits IFN-gamma secretion by human peripheral blood mononuclear cells in the presence of anti-CD3 antibody. The ED₅₀ for this effect is 0.5-2.5 μg/mL.

Reconstitution Calculator

Background: VSIG4

VSIG4 (Vset and immunoglobulin domain containing 4), also known as complement receptor immunoglobulin (CRIg) and Z39IG, is a 45 kDa, type I transmembrane protein of the B7 family within the Ig superfamily that is expressed only in tissue resident macrophages (1-4). The gene is located on the X chromosome (2). Mouse VSIG4 is synthesized as a 280 amino acid (aa) precursor that contains a signal sequence, an IgV-type immunological domain, one potential N-linked glycosylation site, and a single transmembrane domain (4). The IgV domain of mouse VSIG4 shares 86% and 80% aa sequence identity with the IgV domains of rat and human VSIG4, respectively. VSIG4 is specifically expressed on macrophages in the thymic medulla, peritoneum, alveoli, synovia, adipose and heart, liver Kupffer cells, placental Hofbauer cells, and atherosclerotic foam cells (1-4, 6-9). It is absent on infiltrating macrophages (8). VSIG4 is a complement receptor that binds C3b and iC3b fragments, internalizes them to recycling endosomes, and is recycled to the cell surface (4, 6). It contributes significantly to innate immunity by binding and phagocytosis of complement opsonized invading pathogens (4, 8, 10). Binding of either native or recombinant soluble VSIG4 to C3b inhibits complement amplification through the alternative, but not classical, pathway (10, 11). VSIG4 is also a negative regulator of mouse and human T cell activation (2). Although VSIG4 engagement may activate NF kappa B and thus be proinflammatory in some cases, many of its activities are important in resolving, rather than initiating, inflammation (1, 2, 7, 10, 11). There is emerging evidence in human conditions that VSIG-4 may be a valuable biomarker in infection and immunity, inflammatory conditions and cancer prognosis (12-14).

References

He, J.Q. et al. (2008) Mol. Immunol. 45:4041.
Vogt, L. et al. (2006) J. Clin. Invest. 116:2817.
Langnaese, K. et al. (2000) Biochim. Biophys. Acta 1492:522.
Helmy, K.Y. et al. (2006) Cell 124:915.
Entrez protein Accession # EAX05393, NP_001093901, CAI42052, CAI4205, EAX05394.
Tanaka, M. et al. (2008) Clin. Exp. Immunol. 154:38.
Lee, M.Y. et al. (2006) J. Leukoc. Biol. 80:922.
Gorgani, N.N. et al. (2008) J. Immunol. 181:7902.
Walker, M.G. (2002) Biochim. Biophys. Acta 1574:387.
Wiesmann, C. et al. (2006) Nature 444:217.
Katschke, K.J. et al. (2007) J. Exp. Med. 204:1319.
Small, A.G. et al. (2016) Swiss Med. Wkly. 146:w14301.
Roh J., et al. (2017) Oncotarget 8:58122.
Kim K.H., et al. (2016) Autophagy 12:1647.

Long Name

V-Set and Immunoglobulin Domain Containing 4

Entrez Gene IDs

11326 (Human); 278180 (Mouse); 312102 (Rat); 102144784 (Cynomolgus Monkey)

Alternate Names

CRIg; Ig superfamily protein; Protein Z39Ig; V-set and immunoglobulin domain containing 4; V-set and immunoglobulin domain-containing protein 4; VSIG4; Z39IG; Z39IGcomplement receptor of the immunoglobulin superfamily